Recent from talks
2,5-Dimethoxy-4-ethoxyamphetamine
Knowledge base stats:
Talk channels stats:
Members stats:
2,5-Dimethoxy-4-ethoxyamphetamine
2,5-Dimethoxy-4-ethoxyamphetamine (MEM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It was first described by Alexander Shulgin by 1968.
In his book PiHKAL, Alexander Shulgin lists the active dose range of MEM as 20 to 50 mg orally and the duration as 10 to 14 hours. According to Shulgin, MEM produces color enhancement, visual phenomena, and pattern movement, among other effects.
MEM is a serotonergic psychedelic and acts as a selective serotonin 5-HT2 receptor agonist. It is specifically a full agonist of the serotonin 5-HT2A and 5-HT2C receptors and to a lesser extent is a partial to full agonist of the serotonin 5-HT2B receptor. The psychedelic effects of MEM are thought to be mediated by serotonin 5-HT2A receptor activation.
MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine, is a phenethylamine, amphetamine, and DOx derivative. It is the analogue and derivative of 2,4,5-trimethoxyamphetamine (TMA-2) in which a 4-ethoxy group is present instead of a 4-methoxy group.
A variety of derivatives of MEM have been developed and studied, for instance by Daniel Trachsel and colleagues. These include MPM, MIPM, MALM, MMALM, MFEM, MDFEM, and MTFEM, among others.
MEM was first synthesized by Alexander Shulgin. It was first described by him in the scientific literature by 1968. Subsequently, Shulgin described MEM in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Hub AI
2,5-Dimethoxy-4-ethoxyamphetamine AI simulator
(@2,5-Dimethoxy-4-ethoxyamphetamine_simulator)
2,5-Dimethoxy-4-ethoxyamphetamine
2,5-Dimethoxy-4-ethoxyamphetamine (MEM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It was first described by Alexander Shulgin by 1968.
In his book PiHKAL, Alexander Shulgin lists the active dose range of MEM as 20 to 50 mg orally and the duration as 10 to 14 hours. According to Shulgin, MEM produces color enhancement, visual phenomena, and pattern movement, among other effects.
MEM is a serotonergic psychedelic and acts as a selective serotonin 5-HT2 receptor agonist. It is specifically a full agonist of the serotonin 5-HT2A and 5-HT2C receptors and to a lesser extent is a partial to full agonist of the serotonin 5-HT2B receptor. The psychedelic effects of MEM are thought to be mediated by serotonin 5-HT2A receptor activation.
MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine, is a phenethylamine, amphetamine, and DOx derivative. It is the analogue and derivative of 2,4,5-trimethoxyamphetamine (TMA-2) in which a 4-ethoxy group is present instead of a 4-methoxy group.
A variety of derivatives of MEM have been developed and studied, for instance by Daniel Trachsel and colleagues. These include MPM, MIPM, MALM, MMALM, MFEM, MDFEM, and MTFEM, among others.
MEM was first synthesized by Alexander Shulgin. It was first described by him in the scientific literature by 1968. Subsequently, Shulgin described MEM in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Recent media